Adamis Pharmaceuticals Schedules Fourth Quarter and Full Year 2021 Financial Results Conference Call and Business Update

3 years ago

SAN DIEGO, March 24, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty…

Mydecine Receives Conditional IRB Approval for Phase 2b Smoking Cessation Study

3 years ago

Clinical trial programs advance to further assess psychedelic-assisted psychotherapy utilizing lead drug candidate MYCO-001DENVER, March 24, 2022 (GLOBE NEWSWIRE) --…

InflaRx Reports Full Year 2021 Financial and Operating Results

3 years ago

Company received corrected FDA advice letter for Phase III trial with vilobelimab in hidradenitis suppurativaPositive Phase IIa data reported with…

Spectral Announces Fourth Quarter and Fiscal 2021 Results and Corporate Update

3 years ago

TORONTO, March 24, 2022 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage theranostic…

Emerging Markets Report: Love Letters

3 years ago

An Emerging Markets Sponsored Commentary ORLANDO, Fla., March 24, 2022 (GLOBE NEWSWIRE) -- In the world of emergent small cap…

Solei Brand Launches New Wellness Product For Nighttime Use

3 years ago

Renew ‘Moonlight’ by Solei, CBN Vape Pen, Now Available Across Canada Solei Renew Moonlight CBN Solei Renew Moonlight CBNTORONTO, March…

CareDx’s AlloCare App Now Integrated with TxAccess to Help Pre-Transplant Patients Navigate the Waitlist Process

3 years ago

New Features Aim to Help More Patients with Kidney Failure Receive an Organ Transplant CareDx AlloCare transplant app CareDx AlloCare…

Apellis Pharmaceuticals Announces Pricing of Public Offering of Common Stock

3 years ago

WALTHAM, Mass., March 24, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc., (Nasdaq:APLS), a global biopharmaceutical company and leader in complement, today…

Jushi Holdings Inc. Reports Fourth Quarter and Full Year 2021 Financial Results

3 years ago

Fourth Quarter 2021 Revenue of $65.9 million and Full Year 2021 Revenue of $209.3 million, Reflecting 22% Quarterly and 159%…

Freeline Announces Updated Development Plan and Timelines for FLT190 for People with Fabry Disease

3 years ago

Company to progress to second dose cohort in the MARVEL-1 study immediately, with first patient dosing expected in mid-2022 LONDON,…